POM-V
Prescription Required
Companion Animal
Atopica 100 mg/ml Oral Solution for Cats and Dogs
Active ingredient: Ciclosporin A
Form
Liquid
Species
Cats
Dogs
Manufacturer
Elanco GmbH
VMD MA No.
52127/3061
What it's used for
Treatment of chronic manifestations of atopic dermatitis in dogs.
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Cheapest online price
£50.00
from The Pharm Pet Co
5 online retailers compared
Compare all prices View at The Pharm Pet Co →Price drop alert
Enter your email and we'll notify you when this medication drops in price.
You'll be notified!
We'll email you when prices change.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Atopica 100 mg/ml Oral Solution for Cats and Dogs — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.
Treatment of chronic manifestations of atopic dermatitis in dogs.
Before starting treatment, an evaluation of all alternative treatment options should be
made.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
Cats:
The recommended dose of ciclosporin is 7 mg/kg body weight (0.07 ml of oral
solution per kg) and should initially be administered daily. The veterinary medicinal
product should be administered in accordance with the following table:
Bodyweight
(kg)
Dose
(ml)
20.1430.2140.2850.3560.4270.4980.5690.63100.70
AN: 01408/2025Page 6 of 13
The frequency of administration should subsequently be reduced depending on the
response.
The product should initially be given daily until a satisfactory clinical improvement is
seen (assessed by intensity of pruritus and lesion severity - excoriations, miliary
dermatitis, eosinophilic plaques and/or self-induced alopecia). This will generally be
the case within 4-8 weeks.
Once the clinical signs of allergic dermatitis are satisfactorily controlled, the product
can then be given every second day. In some cases where the clinical signs are
controlled with every second day dosing, the veterinary surgeon can decide to give
the product every 3 to 4 days. The lowest effective frequency of dosing should be
used to maintain the remission of clinical signs.
Patients should be regularly re-evaluated and alternative treatment options reviewed.
The duration of treatment should be adjusted according to treatment response.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
The product can be given either mixed with food or directly into the mouth. If given
with food, the solution should be mixed with a small amount of food, preferably after a
sufficient period of fasting to ensure complete consumption by the cat. Should the cat
not accept the product mixed with food, it should be given by inserting the syringe
directly into the cat’s mouth and delivering the entire dose. In case the cat only
partially consumes the product mixed with food, administration of the product with the
syringe should be resumed only the next day.
The efficacy and tolerability of this product was demonstrated in clinical studies with a
duration of 4.5 months.
Dogs:
The mean recommended daily dose of ciclosporin is 5 mg/kg body weight (0.05 ml of
oral solution per kg). The veterinary medicinal product should be administered in
accordance with the following table:
Bodyweight
(kg)
Dose
(ml)
Bodyweight
(kg)
Dose
(ml)
Bodyweight
(kg)
Dose
(ml)
211.05412.05221.10422.1030.15231.15432.1540.20241.20442.2050.25251.25452.2560.30261.30462.3070.35271.35472.3580.40281.40482.4090.45291.45492.45100.50301.50502.50110.55311.55512.55
AN: 01408/2025Page 7 of 13
Bodyweight
(kg)
Dose
(ml)
Bodyweight
(kg)
Dose
(ml)
Bodyweight
(kg)
Dose
(ml)
120.60321.60522.60130.65331.65532.65140.70341.70542.70150.75351.75552.75160.80361.80562.80170.85371.85572.85180.9381.90582.90190.95391.95592.95201.00402.00603.00
The veterinary medicinal product will initially be given daily until a satisfactory clinical
improvement is seen. This will generally be the case within 4 weeks. If no response is
obtained within the first 8 weeks, the treatment should be stopped.
Once the clinical signs of atopic dermatitis are satisfactorily controlled, the veterinary
medicinal product can then be given every other day as a maintenance dose. The
veterinarian should perform a clinical assessment at regular intervals and adjust the
frequency of administration to the clinical response obtained.
In some cases where the clinical signs are controlled with every-other-day dosing,
the veterinarian can decide to give the veterinary medicinal product every 3 to 4
days.
Adjunct treatment (e.g. medicated shampoos, fatty acids) may be considered before
reducing the dosing interval.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
The veterinary medicinal product should be given at least 2 hours before or after
feeding. The product should be given by inserting the syringe directly into the dog’s
mouth and delivering the entire dose.
For the dosing process, carefully follow the handling/dispensing instructions as
described below.
The Dispensing System
The dispensing system consists of:
1. Bottle (5 ml or 17 ml): with rubber stopper
and a child-resistant screw cap.
Bottle (50 ml): with rubber stopper and
aluminum tear-off cap. A separate child-
resistant screw cap is included in the carton.
AN: 01408/2025Page 8 of 13
2.A plastic tube containing
•
an oral dosing syringe
Prepare the Dispensing System
Bottle (5 ml or 17 ml): Push and turn the child-
resistant screw cap to open the bottle.
Bottle (50 ml): Remove aluminum tear-off cap
completely from the bottle.
All bottle sizes (5 ml, 17 ml and 50 ml):
1.Remove and dispose rubber stopper.
2.Hold the open bottle upright on a table and
push the plastic adapter firmly into the
neck of the bottle as far as possible.
3.Close the bottle with the child-resistant
screw cap.
The bottle is now prepared for dispense.
Note: Always close the bottle with the child-
resistant screw cap after use. The adapter must
always remain in the bottle after first use.
AN: 01408/2025Page 9 of 13
Preparing a Dose of Medicine
1.Push and turn the child-resistant screw cap
to open the bottle.
2.Check that the plunger of the appropriate
oral dosing syringe is pushed all the way
down.
3.Keep the bottle upright and insert the
syringe firmly into the plastic adapter.
4.Slowly pull the plunger up to fill the dosing
syringe with medicine.
5.Withdraw the prescribed dose of medicine.
6.Remove the syringe by gently twisting it out
of the plastic adapter.
7.Push the entire dose out of the syringe,
either directly into the mouth of the cat or
dog. For cats, the dose can also mixed into
the cat’s food.
8.Close the bottle with the child-resistant
screw cap after use. Store the syringe in
the plastic tube for further use.
Note:
maximum volume marked on the syringe, you will
need to repeat steps 2 to 7 to administer the
remaining amount of the prescribed dose.
Do not attempt to clean the oral dosing syringe
(e.g. with water) in between uses.
made.
To ensure a correct dosage, body weight should be determined as accurately as
possible.
Cats:
The recommended dose of ciclosporin is 7 mg/kg body weight (0.07 ml of oral
solution per kg) and should initially be administered daily. The veterinary medicinal
product should be administered in accordance with the following table:
Bodyweight
(kg)
Dose
(ml)
20.1430.2140.2850.3560.4270.4980.5690.63100.70
AN: 01408/2025Page 6 of 13
The frequency of administration should subsequently be reduced depending on the
response.
The product should initially be given daily until a satisfactory clinical improvement is
seen (assessed by intensity of pruritus and lesion severity - excoriations, miliary
dermatitis, eosinophilic plaques and/or self-induced alopecia). This will generally be
the case within 4-8 weeks.
Once the clinical signs of allergic dermatitis are satisfactorily controlled, the product
can then be given every second day. In some cases where the clinical signs are
controlled with every second day dosing, the veterinary surgeon can decide to give
the product every 3 to 4 days. The lowest effective frequency of dosing should be
used to maintain the remission of clinical signs.
Patients should be regularly re-evaluated and alternative treatment options reviewed.
The duration of treatment should be adjusted according to treatment response.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
The product can be given either mixed with food or directly into the mouth. If given
with food, the solution should be mixed with a small amount of food, preferably after a
sufficient period of fasting to ensure complete consumption by the cat. Should the cat
not accept the product mixed with food, it should be given by inserting the syringe
directly into the cat’s mouth and delivering the entire dose. In case the cat only
partially consumes the product mixed with food, administration of the product with the
syringe should be resumed only the next day.
The efficacy and tolerability of this product was demonstrated in clinical studies with a
duration of 4.5 months.
Dogs:
The mean recommended daily dose of ciclosporin is 5 mg/kg body weight (0.05 ml of
oral solution per kg). The veterinary medicinal product should be administered in
accordance with the following table:
Bodyweight
(kg)
Dose
(ml)
Bodyweight
(kg)
Dose
(ml)
Bodyweight
(kg)
Dose
(ml)
211.05412.05221.10422.1030.15231.15432.1540.20241.20442.2050.25251.25452.2560.30261.30462.3070.35271.35472.3580.40281.40482.4090.45291.45492.45100.50301.50502.50110.55311.55512.55
AN: 01408/2025Page 7 of 13
Bodyweight
(kg)
Dose
(ml)
Bodyweight
(kg)
Dose
(ml)
Bodyweight
(kg)
Dose
(ml)
120.60321.60522.60130.65331.65532.65140.70341.70542.70150.75351.75552.75160.80361.80562.80170.85371.85572.85180.9381.90582.90190.95391.95592.95201.00402.00603.00
The veterinary medicinal product will initially be given daily until a satisfactory clinical
improvement is seen. This will generally be the case within 4 weeks. If no response is
obtained within the first 8 weeks, the treatment should be stopped.
Once the clinical signs of atopic dermatitis are satisfactorily controlled, the veterinary
medicinal product can then be given every other day as a maintenance dose. The
veterinarian should perform a clinical assessment at regular intervals and adjust the
frequency of administration to the clinical response obtained.
In some cases where the clinical signs are controlled with every-other-day dosing,
the veterinarian can decide to give the veterinary medicinal product every 3 to 4
days.
Adjunct treatment (e.g. medicated shampoos, fatty acids) may be considered before
reducing the dosing interval.
Treatment may be stopped when the clinical signs are controlled. Upon recurrence of
clinical signs, treatment should be resumed at daily dosing, and in certain cases
repeated treatment courses may be required.
The veterinary medicinal product should be given at least 2 hours before or after
feeding. The product should be given by inserting the syringe directly into the dog’s
mouth and delivering the entire dose.
For the dosing process, carefully follow the handling/dispensing instructions as
described below.
The Dispensing System
The dispensing system consists of:
1. Bottle (5 ml or 17 ml): with rubber stopper
and a child-resistant screw cap.
Bottle (50 ml): with rubber stopper and
aluminum tear-off cap. A separate child-
resistant screw cap is included in the carton.
AN: 01408/2025Page 8 of 13
2.A plastic tube containing
•
an oral dosing syringe
Prepare the Dispensing System
Bottle (5 ml or 17 ml): Push and turn the child-
resistant screw cap to open the bottle.
Bottle (50 ml): Remove aluminum tear-off cap
completely from the bottle.
All bottle sizes (5 ml, 17 ml and 50 ml):
1.Remove and dispose rubber stopper.
2.Hold the open bottle upright on a table and
push the plastic adapter firmly into the
neck of the bottle as far as possible.
3.Close the bottle with the child-resistant
screw cap.
The bottle is now prepared for dispense.
Note: Always close the bottle with the child-
resistant screw cap after use. The adapter must
always remain in the bottle after first use.
AN: 01408/2025Page 9 of 13
Preparing a Dose of Medicine
1.Push and turn the child-resistant screw cap
to open the bottle.
2.Check that the plunger of the appropriate
oral dosing syringe is pushed all the way
down.
3.Keep the bottle upright and insert the
syringe firmly into the plastic adapter.
4.Slowly pull the plunger up to fill the dosing
syringe with medicine.
5.Withdraw the prescribed dose of medicine.
6.Remove the syringe by gently twisting it out
of the plastic adapter.
7.Push the entire dose out of the syringe,
either directly into the mouth of the cat or
dog. For cats, the dose can also mixed into
the cat’s food.
8.Close the bottle with the child-resistant
screw cap after use. Store the syringe in
the plastic tube for further use.
Note:
maximum volume marked on the syringe, you will
need to repeat steps 2 to 7 to administer the
remaining amount of the prescribed dose.
Do not attempt to clean the oral dosing syringe
(e.g. with water) in between uses.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.
Do not use in animals with a history of malignant disorders or progressive malignant
disorders.
Do not vaccinate
before or after treatment (see also sections 3.5 “Special precautions for use” and 3.8
“Interaction with other medicinal products and other forms of interaction”).
Do not use in cats infected with FeLV or FIV.
AN: 01408/2025Page 2 of 13
Do not use in dogs less than six months of age or less than 2 kg in weight.
excipients.
Do not use in animals with a history of malignant disorders or progressive malignant
disorders.
Do not vaccinate
before or after treatment (see also sections 3.5 “Special precautions for use” and 3.8
“Interaction with other medicinal products and other forms of interaction”).
Do not use in cats infected with FeLV or FIV.
AN: 01408/2025Page 2 of 13
Do not use in dogs less than six months of age or less than 2 kg in weight.
Cats:
Very common
(>1 animal / 10 animals treated):
Digestive tract disorders (such as Vomiting,
Diarrhoea)
.
Common
(1 to 10 animals / 100 animals
treated):
Lethargy
, Anorexia
, Weight loss
;
Hypersalivation
;
Lymphopenia
.
Very rare
(<1 animal / 10 000 animals
treated, including isolated reports):
Leucopenia, Neutropenia, Thrombocytopenia;
Diabetes mellitus.
generally mild and transient and do not require the cessation of the treatment.
²generally resolve spontaneously after treatment is stopped or following a decrease
in the dosing frequency.
AN: 01408/2025Page 4 of 13
Side effects may be severe in individual animals.
Dogs:
Uncommon
(1 to 10 animals / 1 000 animals
treated):
Digestive tract disorders (such as Hypersalivation,
Vomiting, Mucous stool, Loose stool, Diarrhoea)
.
Rare
(1 to 10 animals / 10 000
animals treated):
Lethargy
, Anorexia
;
Hyperactivity
;
Gingival hyperplasia
2,3
;
Skin reactions (such as Verruciform lesions, Hair
change)
;
Pinnal reddening
, Pinnal oedema
;
Muscle weakness
, Cramp
.
Very rare
(<1 animal / 10 000 animals
treated, including isolated
reports):
Diabetes mellitus
.
generally mild and transient and do not require the cessation of the treatment
generally resolve spontaneously after treatment is stopped
mild to moderate
mainly in West Highland White Terriers
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See ‘Contact details’ of the
package leaflet.
Very common
(>1 animal / 10 animals treated):
Digestive tract disorders (such as Vomiting,
Diarrhoea)
.
Common
(1 to 10 animals / 100 animals
treated):
Lethargy
, Anorexia
, Weight loss
;
Hypersalivation
;
Lymphopenia
.
Very rare
(<1 animal / 10 000 animals
treated, including isolated reports):
Leucopenia, Neutropenia, Thrombocytopenia;
Diabetes mellitus.
generally mild and transient and do not require the cessation of the treatment.
²generally resolve spontaneously after treatment is stopped or following a decrease
in the dosing frequency.
AN: 01408/2025Page 4 of 13
Side effects may be severe in individual animals.
Dogs:
Uncommon
(1 to 10 animals / 1 000 animals
treated):
Digestive tract disorders (such as Hypersalivation,
Vomiting, Mucous stool, Loose stool, Diarrhoea)
.
Rare
(1 to 10 animals / 10 000
animals treated):
Lethargy
, Anorexia
;
Hyperactivity
;
Gingival hyperplasia
2,3
;
Skin reactions (such as Verruciform lesions, Hair
change)
;
Pinnal reddening
, Pinnal oedema
;
Muscle weakness
, Cramp
.
Very rare
(<1 animal / 10 000 animals
treated, including isolated
reports):
Diabetes mellitus
.
generally mild and transient and do not require the cessation of the treatment
generally resolve spontaneously after treatment is stopped
mild to moderate
mainly in West Highland White Terriers
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See ‘Contact details’ of the
package leaflet.
Consideration should be given to the use of other measures and/or treatments to
control moderate to severe pruritus when initiating therapy with ciclosporin.
Special precautions for safe use in the target species:
Clinical signs of atopic or allergic dermatitis such as pruritus and skin inflammation
are not specific for this disease and therefore other causes of dermatitis such as
ectoparasitic infestations, other allergies which cause dermatological signs (e.g. flea
allergic dermatitis or food allergy) or bacterial and fungal infections should be ruled
out before treatment is started. It is good practice to treat flea infestations before and
during treatment of atopic or allergic dermatitis.
A complete clinical examination should be performed before treatment.
It is recommended to clear any infection including bacterial and fungal infections
before administering the veterinary medicinal product. However, infections occurring
during treatment are not necessarily a reason for drug withdrawal, unless the
infection is severe.
While ciclosporin does not induce tumours, it does inhibit T-lymphocytes and
therefore treatment with ciclosporin may lead to an increased incidence of clinically
apparent malignancy due to the decrease in antitumor immune response. The
potentially increased risk of tumour progression must be weighed against the clinical
benefit. If lymphadenopathy is observed in cats and dogs being treated with
ciclosporin, further clinical investigations are recommended and treatment
discontinued if necessary.
In laboratory animals, ciclosporin is liable to affect the circulating levels of insulin and
to cause an increase in glycaemia. In the presence of suggestive signs of diabetes
mellitus, the effect of treatment on glycaemia must be monitored. If signs of diabetes
mellitus are observed following the use of the product, e.g. polyuria or polydipsia, the
dose should be tapered or discontinued and veterinary care sought. The use of
ciclosporin is not recommended in diabetic cats and dogs.
Closely monitor creatinine levels with severe renal insufficiency.
Particular attention must be paid to vaccination. Treatment with the product may
result in decreased immune response to vaccination. It is recommended not to
vaccinate with inactivated vaccines during treatment or within a two-week interval
before or after administration of the product. For live vaccines see also section 3.3
“Contraindications”.
It is not recommended to use immunosuppressive agents concomitantly.
Cats:
Allergic dermatitis in cats can have various manifestations, including eosinophilic
plaques, head and neck excoriation, symmetrical alopecia and/or miliary dermatitis.
AN: 01408/2025Page 3 of 13
The immune status of the cats to FeLV and FIV infections should be assessed before
treatment.
Cats that are seronegative for may be at risk of developing clinical
toxoplasmosis if they become infected while under treatment. In rare cases this can
be fatal. Potential exposure of seronegative cats or cats suspected to be
seronegative to Toxoplasma should therefore be minimised (e.g. keep indoors, avoid
raw meat or scavenging). Ciclosporin was shown to not increase
shedding in a controlled laboratory study. In cases of clinical toxoplasmosis or other
serious systemic illness, stop treatment with ciclosporin and initiate appropriate
therapy.
Clinical studies in cats have shown that decreased appetite and weight loss may
occur during ciclosporin treatment. Monitoring of body weight is recommended.
Significant reduction in body weight may result in hepatic lipidosis. If persistent,
progressive weight loss occurs during treatment it is recommended to discontinue
treatment until the cause has been identified.
The efficacy and safety of ciclosporin has neither been assessed in cats less than 6
months of age nor weighing less than 2.3 kg.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Accidental ingestion of this product may lead to nausea and/or vomiting. To avoid
accidental ingestion, the product must be used and kept out of reach of children. Do
not leave unattended filled syringe in the presence of children. Any uneaten
medicated cat food must be disposed of immediately and the bowl washed
thoroughly. In case of accidental ingestion, particularly by a child, seek medical
advice immediately and show the package leaflet or the label to the physician.
Ciclosporin can trigger hypersensitivity (allergic) reactions. People with known
hypersensitivity to ciclosporin should avoid contact with the product.
This veterinary medicinal product may cause irritation in case of eye contact. Avoid
contact with eyes. In case of contact, rinse thoroughly with clean water. Wash hands
and any exposed skin after administering the veterinary medicinal product..
Special precautions for the protection of the environment:
Not applicable.
control moderate to severe pruritus when initiating therapy with ciclosporin.
Special precautions for safe use in the target species:
Clinical signs of atopic or allergic dermatitis such as pruritus and skin inflammation
are not specific for this disease and therefore other causes of dermatitis such as
ectoparasitic infestations, other allergies which cause dermatological signs (e.g. flea
allergic dermatitis or food allergy) or bacterial and fungal infections should be ruled
out before treatment is started. It is good practice to treat flea infestations before and
during treatment of atopic or allergic dermatitis.
A complete clinical examination should be performed before treatment.
It is recommended to clear any infection including bacterial and fungal infections
before administering the veterinary medicinal product. However, infections occurring
during treatment are not necessarily a reason for drug withdrawal, unless the
infection is severe.
While ciclosporin does not induce tumours, it does inhibit T-lymphocytes and
therefore treatment with ciclosporin may lead to an increased incidence of clinically
apparent malignancy due to the decrease in antitumor immune response. The
potentially increased risk of tumour progression must be weighed against the clinical
benefit. If lymphadenopathy is observed in cats and dogs being treated with
ciclosporin, further clinical investigations are recommended and treatment
discontinued if necessary.
In laboratory animals, ciclosporin is liable to affect the circulating levels of insulin and
to cause an increase in glycaemia. In the presence of suggestive signs of diabetes
mellitus, the effect of treatment on glycaemia must be monitored. If signs of diabetes
mellitus are observed following the use of the product, e.g. polyuria or polydipsia, the
dose should be tapered or discontinued and veterinary care sought. The use of
ciclosporin is not recommended in diabetic cats and dogs.
Closely monitor creatinine levels with severe renal insufficiency.
Particular attention must be paid to vaccination. Treatment with the product may
result in decreased immune response to vaccination. It is recommended not to
vaccinate with inactivated vaccines during treatment or within a two-week interval
before or after administration of the product. For live vaccines see also section 3.3
“Contraindications”.
It is not recommended to use immunosuppressive agents concomitantly.
Cats:
Allergic dermatitis in cats can have various manifestations, including eosinophilic
plaques, head and neck excoriation, symmetrical alopecia and/or miliary dermatitis.
AN: 01408/2025Page 3 of 13
The immune status of the cats to FeLV and FIV infections should be assessed before
treatment.
Cats that are seronegative for may be at risk of developing clinical
toxoplasmosis if they become infected while under treatment. In rare cases this can
be fatal. Potential exposure of seronegative cats or cats suspected to be
seronegative to Toxoplasma should therefore be minimised (e.g. keep indoors, avoid
raw meat or scavenging). Ciclosporin was shown to not increase
shedding in a controlled laboratory study. In cases of clinical toxoplasmosis or other
serious systemic illness, stop treatment with ciclosporin and initiate appropriate
therapy.
Clinical studies in cats have shown that decreased appetite and weight loss may
occur during ciclosporin treatment. Monitoring of body weight is recommended.
Significant reduction in body weight may result in hepatic lipidosis. If persistent,
progressive weight loss occurs during treatment it is recommended to discontinue
treatment until the cause has been identified.
The efficacy and safety of ciclosporin has neither been assessed in cats less than 6
months of age nor weighing less than 2.3 kg.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Accidental ingestion of this product may lead to nausea and/or vomiting. To avoid
accidental ingestion, the product must be used and kept out of reach of children. Do
not leave unattended filled syringe in the presence of children. Any uneaten
medicated cat food must be disposed of immediately and the bowl washed
thoroughly. In case of accidental ingestion, particularly by a child, seek medical
advice immediately and show the package leaflet or the label to the physician.
Ciclosporin can trigger hypersensitivity (allergic) reactions. People with known
hypersensitivity to ciclosporin should avoid contact with the product.
This veterinary medicinal product may cause irritation in case of eye contact. Avoid
contact with eyes. In case of contact, rinse thoroughly with clean water. Wash hands
and any exposed skin after administering the veterinary medicinal product..
Special precautions for the protection of the environment:
Not applicable.
Various substances are known to competitively inhibit or induce the enzymes
involved in the metabolism of ciclosporin, in particular cytochrome P450 (CYP 3A4).
In certain clinically justified cases, an adjustment of the dosage of the veterinary
medicinal product may be required. The compound class of azoles (e.g.
ketoconazole) is known to increase the blood concentration of ciclosporin in cats and
dogs, which is considered to be clinically relevant. Ketoconazole at 5-10 mg/kg is
AN: 01408/2025Page 5 of 13
known to increase the blood concentrations in dogs up to five-fold. During
concomitant use of ketoconazole and ciclosporin the veterinarian should consider as
a practical measure to double the treatment interval if the dog is on a daily treatment
regime. Macrolides such as erythromycin may increase the plasma levels of
ciclosporin up to twofold. Certain inducers of cytochrome P450, anticonvulsants and
antibiotics (e.g. trimethoprim/ sulfadimidine) may lower the plasma concentration of
ciclosporin.
Ciclosporin is a substrate and an inhibitor of the MDR1 P-glycoprotein transporter.
Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as
macrocyclic lactones could decrease the efflux of such drugs from blood-brain barrier
cells, potentially resulting in signs of CNS toxicity. In clinical studies with cats treated
with ciclosporin and selamectin or milbemycin, there did not appear to be an
association between these drugs’ concomitant use and neurotoxicity.
Ciclosporin can increase the nephrotoxicity of aminoglycoside antibiotics and
trimethoprim. The concomitant use of ciclosporin is not recommended with these
active ingredients.
In dogs, no toxicological interactions between ciclosporin and prednisolone (at anti-
inflammatory doses) are expected.
Particular attention must be paid to vaccination (see section 3.3 “Contraindications”
and 3.5 “Special precautions for use”). Concomitant
agents: see section 3.5 “Special precautions for use”.
involved in the metabolism of ciclosporin, in particular cytochrome P450 (CYP 3A4).
In certain clinically justified cases, an adjustment of the dosage of the veterinary
medicinal product may be required. The compound class of azoles (e.g.
ketoconazole) is known to increase the blood concentration of ciclosporin in cats and
dogs, which is considered to be clinically relevant. Ketoconazole at 5-10 mg/kg is
AN: 01408/2025Page 5 of 13
known to increase the blood concentrations in dogs up to five-fold. During
concomitant use of ketoconazole and ciclosporin the veterinarian should consider as
a practical measure to double the treatment interval if the dog is on a daily treatment
regime. Macrolides such as erythromycin may increase the plasma levels of
ciclosporin up to twofold. Certain inducers of cytochrome P450, anticonvulsants and
antibiotics (e.g. trimethoprim/ sulfadimidine) may lower the plasma concentration of
ciclosporin.
Ciclosporin is a substrate and an inhibitor of the MDR1 P-glycoprotein transporter.
Therefore, the co-administration of ciclosporin with P-glycoprotein substrates such as
macrocyclic lactones could decrease the efflux of such drugs from blood-brain barrier
cells, potentially resulting in signs of CNS toxicity. In clinical studies with cats treated
with ciclosporin and selamectin or milbemycin, there did not appear to be an
association between these drugs’ concomitant use and neurotoxicity.
Ciclosporin can increase the nephrotoxicity of aminoglycoside antibiotics and
trimethoprim. The concomitant use of ciclosporin is not recommended with these
active ingredients.
In dogs, no toxicological interactions between ciclosporin and prednisolone (at anti-
inflammatory doses) are expected.
Particular attention must be paid to vaccination (see section 3.3 “Contraindications”
and 3.5 “Special precautions for use”). Concomitant
agents: see section 3.5 “Special precautions for use”.
Store between 15°C and 30°C but preferably not below 20°C for more than one
month.
Storage in the refrigerator should be avoided.
Keep the bottle in the outer carton.
The product contains oily components from natural origin which can become solid at
lower temperatures. A jelly-like formation may occur below 20°C which is however
reversible at temperatures up to 30°C. Minor flakes or a slight sediment may still be
observed. However, this does neither affect the dosing nor the efficacy and safety of
the product.
month.
Storage in the refrigerator should be avoided.
Keep the bottle in the outer carton.
The product contains oily components from natural origin which can become solid at
lower temperatures. A jelly-like formation may occur below 20°C which is however
reversible at temperatures up to 30°C. Minor flakes or a slight sediment may still be
observed. However, this does neither affect the dosing nor the efficacy and safety of
the product.
Not applicable.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Price comparison
Atopica 100 mg/ml Oral Solution for Cats and Dogs Prices by Online retailer
Atopica 100 mg/ml Oral Solution for Cats and Dogs is a prescription-only veterinary medicine (POM-V). Prices are listed for information, with every retailer shown on equal terms. To buy it online you need a written prescription from your vet, which the retailer will ask for at checkout. Under the CMA Order your vet must provide one on request, with the fee capped at £21 from 2027. Your prescription rights →
Price Comparison
The Pharm Pet Co
£50.00
VetMedi
£54.37
Trustpilot: 4.9/5 (3,295 reviews)
· 1
In stock
VetUK
£55.99
Trustpilot: 4.0/5 (25,586 reviews)
· 1
In stock
Animed Direct
£56.49
Trustpilot: 4.6/5 (354,000 reviews)
· 1
In stock
Pet Drugs Online
£59.99
Trustpilot: 2.5/5 (500 reviews)
· 1
In stock
Prices last checked: 2 months ago. Prices may vary. Always confirm with the online retailer before ordering.
We may earn a commission when you buy through our links, at no extra cost to you.
Never miss a renewal
Create a free account to track Atopica 100 mg/ml Oral Solution for Cats and Dogs, set reminders, and compare prices across online retailers.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Ciclosporin A
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Atopica 10 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 10 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Atopica 100 mg/ml Oral Solution for Cats and Dogs
POM-VElanco GmbH
liquid
Cats
Dogs
Atopica 25 mg Soft Capsules for Dogs
POM-VElanco GmbH
capsule
Dogs
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in anti-inflammatory
Related Medications
Adequan 100 mg/ml Solution for Injection
POM-VPolysulphated Glycosaminoglycan
injection
Rx
Horses
Alcort 0.584 mg/ml Cutaneous Spray, Solution
POM-VHydrocortisone Aceponate
spray
Rx
Dogs
Allevinix 50 mg/ml Solution for Injection for Cattle, Horses, Pigs
POM-VFlunixin
injection
Rx
Cattle
Horses
Allevinix 50 mg/ml Solution for Injection for Cattle, Horses, Pigs
POM-VFlunixin
injection
Rx
Cattle
Horses
Anarthron 100 mg/mL Solution for Injection for Dogs
POM-VPentosan Polysulphate Sodium
injection
Rx
Dogs
Anarthron 100 mg/mL Solution for Injection for Dogs
POM-VPentosan Polysulphate Sodium
injection
Rx
Dogs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.